Kura Oncology

KURA

Market cap $854M

FTI mechanism addresses innate and adaptive resistance pathways common to targeted oncology therapies Early clinical and preclinical data support darlifarnib's potential to enhance clinical benefit of PI3Kα -, KRAS- and tyrosine kinase inhibitors 50% objective response rate and 80% disease control rate in renal cell carcinoma (RCC) cohort of darlifarnib plus cabozantinib in ongoing dose-escalation clinical trial Kura Oncology to host a virtual investor event today, October 18, 2025, at 10:30 a.m. PT  /  1:30 p.m.

SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on October 1, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 122,250 shares of common stock to seven (7) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Kura Oncology, Inc. (NASDAQ:KURA ) UBS Virtual Oncology Day October 1, 2025 2:30 PM EDT Company Participants Troy Wilson - Chairman, CEO & President Conference Call Participants Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Xiaochuan Dai UBS Investment Bank, Research Division Hi, everyone. I'm David Dai.

– Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML –

– KOMET-017-IC trial of intensive chemotherapy combination will assess MRD negative CR and EFS as dual-primary endpoints to support potential U.S. accelerated and full approval –

– KOMET-001 in R/R NPM1-m AML met its primary endpoint with ziftomenib monotherapy demonstrating significant clinical benefit and deep responses –

SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in the following investor conference.

Kura Oncology is rated Buy, driven by a strong cash position, strategic Kyowa Kirin partnership, and a robust, diversified pipeline. KURA's lead asset, Ziftomenib, targets AML and awaits a pivotal FDA decision in late 2025, representing a major commercial inflection point. The Kyowa Kirin deal secures substantial non-dilutive funding, global reach, and risk-sharing, supporting KURA through its clinical-to-commercial transition.

Kura Oncology, Inc. - Special Call Company Participants Troy Wilson - Chairman, CEO & President Francis Burrows - Chief Scientific Officer Mollie Leoni - Chief Medical Officer Conference Call Participants Jonathan Chang - Leerink Partners LLC, Research Division Jiale Song - Jefferies LLC, Research Division Yue-Wen Zhu - LifeSci Capital, LLC, Research Division Philip Nadeau - TD Cowen, Research Division Peter Lawson - Barclays Bank PLC, Research Division Salim Syed - Mizuho Securities USA LLC, Research Division Presentation Operator Thank you for standing by and welcome to Kura Oncology's FT Pre-clinical Program Review: Synergistic Combinations with Targeted Therapies. [Operator Instructions] I would now like to hand the call over to Troy Wilson, CEO.

Analyst/Investor event showcases opportunities for KO-2806 (darlifarnib) in combination with PI3Kα  inhibitors, KRAS inhibitors and antiangiogenic tyrosine kinase inhibitors (TKIs)